Langer-in­spired Kala files for an $86M IPO; J&J backs Proven­tion Bio

→  Kala Phar­ma­ceu­ti­cals has filed for an $86 mil­lion IPO, just weeks af­ter the biotech re­port­ed pos­i­tive top line da­ta for a Phase III study of its lead oph­thal­mol­o­gy drug KPI-121. In its S-1 the biotech — co-found­ed by MIT’s Bob Langer — says that it will file its first NDA be­fore the end of this year, with an­oth­er to fol­low in ear­ly 2018. And it’s in two more Phase III stud­ies for dry eye dis­ease with an­oth­er for­mu­la­tion of the lead treat­ment. Kala has tried to pull off an IPO dur­ing try­ing times for biotech stocks. Now the mar­ket has been boom­ing for a few days at least and biotech IPOs have been lin­ing up to take ad­van­tage of grow­ing ev­i­dence that in­vestors are once again in­vest­ing in risky plays.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER